SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae.

Big Pharma executives have not been shy about their desire for deals, but companies have been battling macro headwinds ...

Supernus Pharmaceuticals (Nasdaq: SUPN) is to buy Sage Therapeutics (Nasdaq: SAGE) for total consideration of around $795 million. Shares in Sage shot up by 35% amid the news by midday Monday, while ...